Astorg Acquires Majority Interest in Avania

Avania | June 21, 2022

Avania, the preeminent, full-service global MedTech contract research organization announced that Astorg has acquired a majority stake in the company. Astorg, together with Kester Capital current investor who intends to retain a minority stake will actively support management’s plans to advance Avania’s development as a MedTech solution provider.

Headquartered in the Netherlands, Avania was formed in March 2020 from the combination of five complementary businesses and started a successful journey to establish a fully integrated platform to serve sponsors worldwide in advancing medical technology products from early development to post-market ensuring customized, scalable solutions that optimize efficiencies and streamline the advancement of medical technology.

Astorg brings an impressive global network of relationships in the MedTech space which will strengthen Avania’s pipeline and broaden its customer base while the capital access will help accelerate its growth, both organically and via acquisitions.

“The platform we have built has positioned us ahead of our competition in the MedTech CRO space, and this deal will bring additional investment to strengthen our infrastructure, capital for acquisitions, and added support as we continue to grow Avania into the clear market leader. The largest CROs do not have the specialization that we bring, and the regional niche providers do not have the scale and reach of Avania. This unique positioning, along with the continued changes to the MedTech regulatory landscape, will allow us to push ourselves to the next era of growth.”

Sapna Hornyak, president and CEO of Avania

“We are extremely pleased to partner with Sapna and her team, as well as Kester, on this transaction,” said Managing Partner of Astorg Mid-Cap Edouard Pillot. “Being one of the global leaders in a profitable and fast-growing niche market, Avania squarely fits with Astorg’s investment criteria, and we are delighted to have Avania as our first Mid-Cap Healthcare deal, sitting within Astorg’s broader healthcare portfolio.”

About Avania

Avania is a leading, global full-service contract research organization focused on the management of clinical studies for medical technology, IVDs, biologics, and device-drug combination products internationally. Avania supports products from the first-in-human phase through the post-market phase with the same customized approach. When you need to advance your medical technology, it takes Avania. Avania’s vision is to be your trusted global partner in the evolution of your medical technology from innovation to commercialization to improving patient health and well-being.

About Astorg

Astorg is a leading private equity firm with over €17 billion of assets under management. We work with entrepreneurs and management teams to acquire market-leading global companies headquartered in Europe or the US, providing them with the strategic guidance, governance, and capital they need to achieve their growth goals. Astorg enjoys a distinct entrepreneurial culture, a long-term shareholder perspective, and a lean decision-making body. We have valuable industry expertise in healthcare, software, business-to-business professional services and technology-based industrial companies. Astorg has offices in London, Paris, New York, Frankfurt, Milan and Luxembourg.

About Kester Capital

Kester Capital is a primary buy-out specialist. Kester focuses on the healthcare, data & information and technology sectors, targeting businesses that require capital in order to unlock their potential.

Spotlight

EXT 220 MED: The first 3D printing platform specifically designed for healthcare.

The EXT 220 MED 3D printer enables manufacturers and hospitals to 3D print medical implants and instruments using high performance polymers such as PEEK and Radel® PPSU. It is the only extrusion printer that features an integrated clean room and is validated by leading medical device manufacturers and hospitals worldwide.

More featured news

Spotlight

EXT 220 MED: The first 3D printing platform specifically designed for healthcare.

Related News

Digital Healthcare, Medical Devices

Massive Bio and Datavant Expand Partnership to Integrate Datavant’s Medical Record Retrieval Capabilities to Revolutionize Patient Care

Globenewswire | July 03, 2023

Massive Bio, a leader in leveraging artificial intelligence and concierge services to empower cancer patients, and Datavant, the leader in helping organizations securely connect data, are thrilled to announce an expanded partnership that leverages Datavant’s national scale in medical record retrieval and Massive Bio’s expertise in AI-driven clinical trial matching to accelerate clinical research and improve patient care in cancer. This expanded partnership builds upon an earlier pilot that enabled Massive Bio to request, retrieve, and digitally deliver clinical data with higher reliability, faster speed and greater coverage across sites of care, thus significantly improving patient outcomes while ensuring compliance and data privacy. Massive Bio's CEO, Selin Kurnaz, emphasizing the significance of this partnership states, "By integrating Datavant's cutting-edge technology, we are making a leap in the provision of personalized cancer treatments. This collaboration empowers us to access patient medical records for any patient in the country in a scalable, secure and compliant manner, thereby accelerating our ability to provide data-driven, personalized care." Dr. Arturo Loaiza-Bonilla, Co-Founder and Chief Medical Officer at Massive Bio, adds, "By leveraging the Datavant Switchboard, we are strategically positioned to drive meaningful cost savings while improving patient care. Especially for our oncology patients, the ability to obtain complete clinical histories from the medical record would be a challenge. We are thrilled to be working with Datavant, whose national scale of data connectivity can help us access full medical records, including unstructured data, that is essential to our work. Datavant is transforming how clinical data is used and shared, ultimately bringing us closer to achieving our mission of providing the right treatment to the right patient at the right time." "We are excited about this partnership with Massive Bio. Their innovative approach to personalized cancer care aligns with our mission of securely connecting health data to improve patient outcomes," says Tal Rosenberg, President, Emerging Businesses & Chief Partnerships Officer at Datavant. "This collaboration not only marks a significant step forward in patient care but also emphasizes our shared commitment to reducing friction and increasing security in health data exchange." With this expanded partnership, Massive Bio will integrate Datavant’s medical record retrieval capabilities into Massive Bio’s operations in order to expedite the identification of potential clinical trial participants and speed up time to insight in clinical research. About Datavant Datavant's mission is to connect the world's health data to improve patient outcomes. Datavant works to reduce the friction of data sharing across the healthcare industry by building technology that protects the privacy of patients while supporting the linkage of patient health records across datasets. About Massive Bio Massive Bio is at the forefront of empowering cancer patients to discover their optimal treatment options. Utilizing AI to enhance equitable access and precision targeting for clinical trial matching, drug matching, and drug development, Massive Bio is committed to breaking down barriers in clinical trial enrollment, fostering value-based oncology decisions, and facilitating data-driven cancer treatment. Serving over three dozen pharmaceutical companies, contract research organizations, and hospital networks, Massive Bio has earned recognition from the National Cancer Institute with an SBIR contract. Founded in 2015 by a team of clinical, technology, and M&A executives, Massive Bio boasts a global presence with nearly 100 people across 12 countries.

Health Technology, Healthcare Analytics

Capital Rx Launches Rx Reverse in Partnership with Virta Health to Combat Type 2 Diabetes and Obesity

PRNewswire | July 18, 2023

Capital Rx, the health technology company changing the way prescription drugs are priced and patients are cared for, and type 2 diabetes (T2D) reversal leader Virta Health have partnered to introduce Rx Reverse. Available to all of Capital Rx's customers, Rx Reverse is a high-touch, provider-led, integrated clinical program designed to help members reverse T2D and fight obesity without costly medications. The problem is clear: 37+ million Americans have been diagnosed with diabetes, and over 90% of them have T2D (including one-third of the population over 65 years old).1 At the same time, the prevalence of obesity is over 40% of the U.S. population2 and is expected to reach nearly 50% by 2030.3 During a June 15, 2023 webinar, Rethinking Obesity Strategies: The Rise of GLP-1 Drugs and Lifestyle Programs for Weight Loss, Virta revealed new survey data highlighting that diabetes and obesity are the #1 and #2 concerns of health plan leaders in 2023 because of rising costs and downstream health impact. The launch of Rx Reverse comes as demand for GLP-1 drugs approved for diabetes and weight loss is rising rapidly, and employers and health plan leaders focus on managing the cost of diabetes and obesity. Rx Reverse combines Capital Rx's tech-enabled pharmacy benefit management (PBM) service model, powered by JUDI®, and Virta's solution – personalized nutrition therapy, physician-led deprescription, remote monitoring, and one-on-one coaching – to help health plans reduce costs and improve members' health. "Leveraging JUDI, our proprietary next-generation claim adjudication platform for Medicare, Medicaid, and commercial plans, we have the ability to seamlessly connect with vendors like Virta, sharing actionable member information efficiently in real-time, and providing the connectivity plan members need to improve their overall health," said Sara Izadi, PharmD, Senior Vice President of Pharmacy at Capital Rx. "Our Single-Ledger Model™, coupled with JUDI's capabilities, enables us to partner with Virta on a solution focused on deprescribing and health equity." Virta reports lowering HbA1c for patients by 1.3% on average after one year, and 60% of patients enrolled one year attained an HbA1c below 6.5% without using diabetes medications other than metformin. Moreover, patients experience an average of 12% body weight loss at two years. And like Capital Rx, which saves payers 10% - 30% in the first year, on average, after switching from a traditional PBM model, Virta emphasizes positive financial outcomes, including demonstrating an estimated $503 per engaged member per month gross savings for T2D reversal participants. Three Rx Reverse options are available for plan sponsors to choose from Type 2 Diabetes Reversal: Helps plan members achieve lower blood sugar – often to sub-diabetes levels <6.5 A1c – and clinically significant weight loss alongside safe deprescription of diabetes medication. Provider-Led Weight Loss: Helps plan members without diabetes who are considered overweight (BMI ≥ 25) or obese (BMI ≥ 30) achieve clinically significant weight loss. Type 2 Diabetes Reversal & Provider-Led Weight Loss "The rapidly rising utilization and cost of obesity and diabetes drugs is putting extreme pressure on healthcare payers," said Kevin Kumler, President at Virta Health. "Capital Rx's tech-forward, value-based approach – a needed evolution from the traditional PBM model – aligns both incentives and systems to help payers control drug costs while members get healthier." About Virta Health Virta Health is the leader in type 2 diabetes reversal and is creating a new standard in medical care for people living with type 2 diabetes, prediabetes, or obesity. The company's virtual approach combines personalized nutrition therapy with continuous provider-led support to empower members to eliminate medications, lose weight, and take back their lives. Virta has earned the trust of the nation's largest organizations, including Humana, AutoZone, and Blue Shield of California, delivering industry-leading cost savings of over $6,000 per member per year while putting our fees at risk based on health outcomes. About Capital Rx Capital Rx is a healthcare technology company changing the way prescription drugs are priced and patients are cared for in America. As a Certified B Corp™, Capital Rx is executing its mission through a Single-Ledger Model™, the industry's first ethical framework for drug pricing. The company's cloud-native enterprise pharmacy platform, JUDI®, connects every aspect of the pharmacy ecosystem, servicing over 2.4 million members for Medicare, Medicaid, and commercial plans.

Health Technology, AI

NextGen Healthcare and Luma Health Announce Strategic Alliance to Offer AI-Enhanced Solutions for Patient Engagement

prnewswire | August 25, 2023

NextGen Healthcare Inc. a leading provider of innovative, cloud-based healthcare technology solutions, and Luma Health, innovator of the market-leading Patient Success Platform™, announced an expanded alliance to equip ambulatory organizations nationwide with artificial intelligence (AI)-enhanced solutions for patient communications, beginning with intake and self-scheduling. NextGen® Patient Engage and NextGen® Self-Scheduling powered by Luma will enable patients to conveniently engage with their care providers in more than 20 languages from their mobile devices. Integrated seamlessly into NextGen Enterprise electronic health records (EHR), these solutions enable patients to confirm or cancel appointments, interact with staff, provide relevant documents, and complete pre-visit intake forms from the comfort of their homes without logging into a portal. NextGen Healthcare clients will have the ability to send appointment reminders and surveys, invite patients to join the "smart" waitlist for earlier appointments that match their existing appointment type, announce new service lines, and share other time-sensitive updates. The technology employs AI and natural-language processing to provide automated conversational responses to patient texts, reducing manual work and double-documentation for staff. All communications are secure and HIPAA-compliant. "Luma has a proven record of success in creating digital engagement solutions that address the complete patient journey and meaningfully improve the care experience for patients, providers, and staff," said Srinivas (Sri) Velamoor, chief growth & strategy officer for NextGen Healthcare. "We are enthusiastic about this alliance and proud of how the enhanced offerings will empower patients to take even greater ownership of their care." "We're thrilled to enter this strategic alliance to bring the power of Luma's comprehensive Patient Success Platform™ to NextGen Healthcare's extensive client bases. Luma's market-leading capabilities natively integrated with award-winning NextGen Enterprise will help patients and providers partner together and will create scalable patient, staff, and system success," said Aditya Bansod, chief technology officer and co-founder of Luma. "Together, our platforms will enable healthcare organizations to grow, while elevating the patient and provider experience." Luma already powers more than 500,000 patient engagements per day. Existing user Houston ENT & Allergy, a NextGen Healthcare client and one of the nation's largest ENT clinics, has seen increased revenues of $1.2 million with the adoption of Luma's smart waitlist and other products across 10 Houston, Texas, sites of care. "The combined Luma Health and NextGen Healthcare patient engagement solutions are helping us meet our modern patient population exactly where they want us to be – on their phone or anytime they need care," said Chuck Leider, CEO of Houston ENT & Allergy. "These solutions will keep us competitive for many years to come, as patients can schedule appointments any time they need, without playing phone tag or sitting on hold. Similarly, the solutions enable our staff to be more productive and increase job satisfaction by reducing provider burden." About Luma Health Luma was founded on the idea that healthcare should work better for all patients. Instead of a disconnected experience, where patients are forced to be their own healthcare advocates and provider teams struggle to reach their patients, every point along the care journey should be simple, seamless, and effective. Luma's Patient Success Platform™ empowers patients and providers to be successful by connecting and orchestrating all the steps in the patient journey, along with all the operational workflows and processes in the healthcare ecosystem. Headquartered in San Francisco, Luma serves more than 600 health systems, integrated delivery networks, federally qualified health centers, specialty networks, and clinics across the United States, and today orchestrates the care journeys of more than 35 million patients. About NextGen Healthcare Inc.   NextGen Healthcare Inc. is a leading provider of innovative healthcare technology solutions. We are reimagining ambulatory healthcare with award-winning solutions that enable high-performing practices to create healthier communities. We partner with medical, behavioral, and oral health providers in their journey toward whole-person health and value-based care. Our highly integrated, intelligent, and interoperable solutions go beyond EHR and Practice Management to increase clinical quality and productivity, enrich the patient experience and drive superior financial performance. We are on a quest to achieve better healthcare outcomes for all.